Table 2 Characteristics, findings, treatments, and clinical outcome of reported Myasthenia gravis cases

22

64 (50, 74)

18 (82%)

12 (55%)

mRNA-based vaccine^a

1st dose / 2nd dose / Booster

14

5 (36%) / 5 (36%) / 4 (28%)

Vector-based vaccine^b

1st dose / 2nd dose

8

7 (88%) / 1 (12%)

Presenting symptoms

Diplopia / Ptosis^c / Dysarthria / Dysphagia / Extremity asthenia

13

10(77%)/ 6(46%)/ 3(23%)/ 3(23%)/ 1(8%)

22

6 (2, 8.5)

 Imaging

Normal Brain CT scan

5

5 (100%)

Normal Brain MRI

6

5 (83%)

Thymus hyperplasia on Chest CT scan

8

2 (25%)

 Tests in the clinic

Positive Ice pack test

2

2 (100%)

Positive IM neostigmine test

4

3 (75%)

 EMG

Positive RNS

15

13 (87%)

Positive SFEMG

4

4 (100%)

 Seropositivity

Only AChR Ab positive (MuSK not tested)

16

14 (87%)

AChR positive & MuSK negative

4

2 (50%)

AChR negative & MuSK negative

2 (50%)

19

7 (33%) / 7 (33%) / 1 (5%) / 1 (5%)

2 (10%) / 2 (10%) / 1 (5%)

14

7 (50%) / 4 (29%)

2 (14%) / 1 (7%)